Literature DB >> 22554690

Hereditary spastic paraplegias with autosomal dominant, recessive, X-linked, or maternal trait of inheritance.

Josef Finsterer1, Wolfgang Löscher, Stefan Quasthoff, Julia Wanschitz, Michaela Auer-Grumbach, Giovanni Stevanin.   

Abstract

Hereditary spastic paraplegia (SPG) is a clinically and genetically heterogeneous group of neurodegenerative disorders that are clinically characterised by progressive spasticity and weakness of the lower-limbs (pure SPG) and, majoritorian, additional more extensive neurological or non-neurological manifestations (complex or complicated SPG). Pure SPG is characterised by progressive spasticity and weakness of the lower-limbs, and occasionally sensory disturbances or bladder dysfunction. Complex SPGs additionally include cognitive impairment, dementia, epilepsy, extrapyramidal disturbances, cerebellar involvement, retinopathy, optic atrophy, deafness, polyneuropathy, or skin lesions in the absence of coexisting disorders. Nineteen SPGs follow an autosomal-dominant (AD-SPG), 27 an autosomal-recessive (AR-SPG), 5 X-linked (XL-SPG), and one a maternal trait of inheritance. SPGs are due to mutations in genes encoding for proteins involved in the maintenance of corticospinal tract neurons. Among the AD-SPGs, 40-45% of patients carry mutations in the SPAST-gene (SPG4) and 10% in the ATL1-gene (SPG3), while the other 9 genes are more rarely involved (NIPA1 (SPG6), KIAA0196 (SPG8), KIF5A (SPG10), RNT2 (SPG12), SPGD1 (SPG13), BSCL2 (SPG17), REEP1 (SPG31), ZFYVE27 (SPG33, debated), and SLC33A1 (SPG42, debated)). Among the AR-SPGs, ~20% of the patients carry mutations in the KIAA1840 (SPG11) gene whereas the 15 other genes are rarely mutated and account for SPGs in single families yet (CYP7B1 (SPG5), SPG7 (SPG7), ZFYVE26 (SPG15), ERLIN2 (SPG18), SPG20 (SPG20), ACP33 (SPG21), KIF1A (SPG30), FA2H (SPG35), NTE (SPG39), GJA12/GJC2 (SPG44), KIAA0415 (SPG48) and 4 genes encoding for the AP4-complex (SPG47)). Among the XL-SPGs, 3 causative genes have been identified (L1CAM (SPG1), PLP1 (SPG2), and SLC16A2 (SPG22)). The diagnosis of SPGs is based on clinical, instrumental and genetic investigations. Treatment is exclusively symptomatic.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22554690     DOI: 10.1016/j.jns.2012.03.025

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  99 in total

1.  Spastic paraplegia proteins spastizin and spatacsin mediate autophagic lysosome reformation.

Authors:  Jaerak Chang; Seongju Lee; Craig Blackstone
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

2.  Characterization of Alu and recombination-associated motifs mediating a large homozygous SPG7 gene rearrangement causing hereditary spastic paraplegia.

Authors:  Eva López; Carlos Casasnovas; Javier Giménez; Antoni Matilla-Dueñas; Ivelisse Sánchez; Víctor Volpini
Journal:  Neurogenetics       Date:  2014-11-16       Impact factor: 2.660

3.  Exome sequencing in a family with intellectual disability, early onset spasticity, and cerebellar atrophy detects a novel mutation in EXOSC3.

Authors:  Ginevra Zanni; Chiara Scotton; Chiara Passarelli; Mingyan Fang; Sabina Barresi; Bruno Dallapiccola; Bin Wu; Francesca Gualandi; Alessandra Ferlini; E Bertini; Wang Wei
Journal:  Neurogenetics       Date:  2013-08-24       Impact factor: 2.660

Review 4.  Hereditary Spastic Paraplegia: Clinical and Genetic Hallmarks.

Authors:  Paulo Victor Sgobbi de Souza; Wladimir Bocca Vieira de Rezende Pinto; Gabriel Novaes de Rezende Batistella; Thiago Bortholin; Acary Souza Bulle Oliveira
Journal:  Cerebellum       Date:  2017-04       Impact factor: 3.847

5.  Molecular epidemiology and clinical spectrum of hereditary spastic paraplegia in the Japanese population based on comprehensive mutational analyses.

Authors:  Hiroyuki Ishiura; Yuji Takahashi; Toshihiro Hayashi; Kayoko Saito; Hirokazu Furuya; Mitsunori Watanabe; Miho Murata; Mikiya Suzuki; Akira Sugiura; Setsu Sawai; Kazumoto Shibuya; Naohisa Ueda; Yaeko Ichikawa; Ichiro Kanazawa; Jun Goto; Shoji Tsuji
Journal:  J Hum Genet       Date:  2014-01-23       Impact factor: 3.172

6.  Loss of function of glucocerebrosidase GBA2 is responsible for motor neuron defects in hereditary spastic paraplegia.

Authors:  Elodie Martin; Rebecca Schüle; Katrien Smets; Agnès Rastetter; Amir Boukhris; José L Loureiro; Michael A Gonzalez; Emeline Mundwiller; Tine Deconinck; Marc Wessner; Ludmila Jornea; Andrés Caballero Oteyza; Alexandra Durr; Jean-Jacques Martin; Ludger Schöls; Chokri Mhiri; Foudil Lamari; Stephan Züchner; Peter De Jonghe; Edor Kabashi; Alexis Brice; Giovanni Stevanin
Journal:  Am J Hum Genet       Date:  2013-01-17       Impact factor: 11.025

7.  Early-onset optic neuropathy as initial clinical presentation in SPG7.

Authors:  Christian Marcotulli; Luca Leonardi; Alessandra Tessa; Anna Maria De Negris; Riccardo Cornia; Alberto Pierallini; Shalom Haggiag; Francesco Pierelli; Filippo M Santorelli; Carlo Casali
Journal:  J Neurol       Date:  2014-07-18       Impact factor: 4.849

Review 8.  Mendelian neurodegenerative disease genes involved in autophagy.

Authors:  Lidia Wróbel; Sandra Malmgren Hill; Claudia Puri; Sung Min Son; Motoki Fujimaki; Ye Zhu; Eleanna Stamatakou; Farah Siddiqi; Marian Fernandez-Estevez; Marco M Manni; So Jung Park; Julien Villeneuve; David Chaim Rubinsztein
Journal:  Cell Discov       Date:  2020-05-05       Impact factor: 10.849

9.  Three novel mutations in 20 patients with hereditary spastic paraparesis.

Authors:  Mehmet Bugrahan Duz; Selcuk Dasdemir; Aysel Kalayci Yigin; Mehmet Ali Akalin; Mehmet Seven
Journal:  Neurol Sci       Date:  2018-06-16       Impact factor: 3.307

10.  Hereditary spastic paraplegias: identification of a novel SPG57 variant affecting TFG oligomerization and description of HSP subtypes in Sudan.

Authors:  Liena E O Elsayed; Inaam N Mohammed; Ahlam A A Hamed; Maha A Elseed; Adam Johnson; Mathilde Mairey; Hassab Elrasoul S A Mohamed; Mohamed N Idris; Mustafa A M Salih; Sarah M El-Sadig; Mahmoud E Koko; Ashraf Y O Mohamed; Laure Raymond; Marie Coutelier; Frédéric Darios; Rayan A Siddig; Ahmed K M A Ahmed; Arwa M A Babai; Hiba M O Malik; Zulfa M B M Omer; Eman O E Mohamed; Hanan B Eltahir; Nasr Aldin A Magboul; Elfatih E Bushara; Abdelrahman Elnour; Salah M Abdel Rahim; Abdelmoneim Alattaya; Mustafa I Elbashir; Muntaser E Ibrahim; Alexandra Durr; Anjon Audhya; Alexis Brice; Ammar E Ahmed; Giovanni Stevanin
Journal:  Eur J Hum Genet       Date:  2016-09-07       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.